BioCentury
ARTICLE | Product Development

Arcutis eyes broader market for roflumilast

New Phase III data from a foam version of roflumilast could help Arcutis grab a larger share of the psoriasis market

September 27, 2022 9:44 PM UTC

In the midst of launching Zoryve cream for plaque psoriasis, Arcutis has taken another step toward realizing the drug's pipeline-in-a-product potential with a second Phase III win for a foam formulation of the drug. 

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) announced positive top-line results from the Phase III ARRECTOR trial evaluating roflumilast foam 0.3%, a once-daily, non-steroidal topical PDE-4 inhibitor, to treat scalp and body psoriasis. ARRECTOR is the second Phase III trial of the foam to meet its endpoint this year; the first was in patients with seborrheic dermatitis...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article